IQVIA MedTech is uniquely positioned to give immediate insights into the dynamics of GLP-1 markets and patient profiles at the global, national, and regional levels, coupled with deep market expertise needed to uncover the vital insights needed
Really helpful in designing professional presentations
Konkel, S
Unlike sodium-glucose cotransporter-2 (SGLT-2) inhibitorsanother class of diabetes medicationssemaglutide does not alter urinary glucose levels or create a glucose-rich environment in the urinary tract that would promote bacterial growth
Lohman, MD, Bariatric Medicine, Family Medicine, Nuvance Health now part of Northwell Health WESTPORTWestporters have felt the impact of rising medical costs more acutely than ever, especially when it comes to GLP-1 medications widely used for weight loss, diabetes and long-term metabolic health
How the Transition from Semaglutide to Tirzepatide Works Most clinicians recommend a gradual transition rather than an abrupt switch to minimize gastrointestinal upset